Gain Therapeutics Valuation
| GANX Stock | USD 2.36 0.07 3.06% |
Based on Macroaxis valuation methodology, the firm appears to be undervalued. Gain Therapeutics retains a regular Real Value of $3.44 per share. The prevalent price of the firm is $2.36. Our model calculates the value of Gain Therapeutics from evaluating the firm fundamentals such as Shares Owned By Insiders of 5.00 %, return on asset of -0.94, and Return On Equity of -2.63 as well as inspecting its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Gain Therapeutics' valuation include:
Price Book 7.3537 | Enterprise Value | Enterprise Value Ebitda (1.55) | Price Sales 925.9162 | Enterprise Value Revenue 138.3348 |
Undervalued
Today
Please note that Gain Therapeutics' price fluctuation is very risky at this time. Calculation of the real value of Gain Therapeutics is based on 3 months time horizon. Increasing Gain Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Gain Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Gain Stock. However, Gain Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 2.36 | Real 3.44 | Target 7.33 | Hype 2.17 | Naive 2.92 |
The intrinsic value of Gain Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Gain Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Gain Therapeutics helps investors to forecast how Gain stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Gain Therapeutics more accurately as focusing exclusively on Gain Therapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Gain Therapeutics' intrinsic value based on its ongoing forecasts of Gain Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Gain Therapeutics' closest peers.
Gain Therapeutics Cash |
|
Gain Valuation Trend
Analysing the historical paterns of Gain Therapeutics' enterprise value and its market capitalization is a good way to estimate and gauge the value of Gain Therapeutics over time and is usually enough for investors to make rational market timing decisions.
Gain Therapeutics Total Value Analysis
Gain Therapeutics is currently estimated to have valuation of 54.24 M with market capitalization of 65.52 M, debt of 1.03 M, and cash on hands of 24.25 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Gain Therapeutics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
54.24 M | 65.52 M | 1.03 M | 24.25 M |
Gain Therapeutics Investor Information
The company recorded a loss per share of 1.07. Gain Therapeutics had not issued any dividends in recent years. Based on the key indicators related to Gain Therapeutics' liquidity, profitability, solvency, and operating efficiency, Gain Therapeutics is not in a good financial situation at this time. It has a very high odds of going through financial crisis in April.Gain Therapeutics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Gain Therapeutics has an asset utilization ratio of 0.3 percent. This suggests that the Company is making $0.002965 for each dollar of assets. An increasing asset utilization means that Gain Therapeutics is more efficient with each dollar of assets it utilizes for everyday operations.Gain Therapeutics Ownership Allocation
Gain Therapeutics has a total of 26.53 Million outstanding shares. Gain Therapeutics retains 5.0 (percent) of its outstanding shares held by insiders and 7.64 (percent) owned by outside corporations. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.Gain Therapeutics Profitability Analysis
The company reported the previous year's revenue of 55.18 K. Net Loss for the year was (22.27 M) with loss before overhead, payroll, taxes, and interest of (11.46 M).About Gain Therapeutics Valuation
Our relative valuation model uses a comparative analysis of Gain Therapeutics. We calculate exposure to Gain Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Gain Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -22.7 K | -23.8 K | |
| Pretax Profit Margin | (462.42) | (439.30) | |
| Operating Profit Margin | (463.77) | (440.59) | |
| Net Loss | (464.07) | (440.87) | |
| Gross Profit Margin | (0.41) | (0.43) |
Gain Therapeutics Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 13 M |
Gain Therapeutics Current Valuation Indicators
Valuation refers to the process of determining the present value of Gain Therapeutics and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Gain we look at many different elements of the entity such as Gain's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Gain Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Gain Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Gain Therapeutics' worth.Additional Tools for Gain Stock Analysis
When running Gain Therapeutics' price analysis, check to measure Gain Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Gain Therapeutics is operating at the current time. Most of Gain Therapeutics' value examination focuses on studying past and present price action to predict the probability of Gain Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Gain Therapeutics' price. Additionally, you may evaluate how the addition of Gain Therapeutics to your portfolios can decrease your overall portfolio volatility.